A new model aimed at encouraging the development of new antibiotics was presented recently by OHE’s Chris Hoyle, who collaborated with Adrian Towse and Jorge Mestre-Ferrandiz in designing the model.
Antimicrobial resistance to existing antibiotics is an increasingly serious global health issue that extends to a number of diseases. Earlier OHE research defined the parameters of policy options, which must achieve two objectives: (1) encourage the development of new antibiotics to treat resistant microbes and (2) discourage the overuse that produces resistance.
Chris’s presentation summarises the OHE model, which takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. It concludes that traditional incentives for R&D/market exclusivity are likely to be insufficient to spur development, and that uncertainty and risk are too great for price alone to provide sufficient incentive. The most effective solution couples an advance market commitment, at national or supranational level, with careful local pricing.
OHE’s previous work on this issue has included thorough analyses of the policy issues worldwide as well as policy options specifically for use in discussion in the EU. For information about this research, please click on the "countering AMR" category on our blog at news.ohe.org.
A new model aimed at encouraging the development of new antibiotics was presented recently by OHE’s Chris Hoyle, who collaborated with Adrian Towse and Jorge Mestre-Ferrandiz in designing the model.
Antimicrobial resistance to existing antibiotics is an increasingly serious global health issue that extends to a number of diseases. Earlier OHE research defined the parameters of policy options, which must achieve two objectives: (1) encourage the development of new antibiotics to treat resistant microbes and (2) discourage the overuse that produces resistance.
Chris’s presentation summarises the OHE model, which takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. It concludes that traditional incentives for R&D/market exclusivity are likely to be insufficient to spur development, and that uncertainty and risk are too great for price alone to provide sufficient incentive. The most effective solution couples an advance market commitment, at national or supranational level, with careful local pricing.
OHE’s previous work on this issue has included thorough analyses of the policy issues worldwide as well as policy options specifically for use in discussion in the EU. For information about this research, please click on the "countering AMR" category on our blog at news.ohe.org.
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Dr. Julie Lyn Hall, WHO Country Representative for the Philippines, discusses the strategies of the WPRO in handling and preventing EIDs like Ebola and MERS-CoV in our region
Bio-pharmaceuticals Industry in India (2018-2023) - Snippets of the Market Re...Research On Global Markets
Bio-pharmaceutical products are manufactured in the form of complex macromolecules developed through genetic manipulation of living organisms using gene cloning, recombination of DNA and cell fusion. India caters to nearly 50% of the global demand for pharmaceutical products, most of which are based on the usage of biotechnological applications.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
Briefing based on the key findings of my research on the Global Generic Pharmaceuticals Market 2010, covering the developed markets like the U.S, Germany, UK, France, Italy and Spain as well as the emerging markets such as India and China.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The way we bring new medicines to life is changing. Regulators, scientists and healthcare professionals are working together to ensure access to new medicines and other therapies is accelerated.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
Dr. Julie Lyn Hall, WHO Country Representative for the Philippines, discusses the strategies of the WPRO in handling and preventing EIDs like Ebola and MERS-CoV in our region
ILRI’s key programs to address infectious diseases, areas requiring internati...ILRI
Presentation by Fred Unger, Hu Suk Lee, Edward Okoth, Bernard Bett and Hung Nguyen-Viet at the Global ODA Forum for Sustainable Agricultural Development, Seoul, South Korea, 22 November 2022.
China Vaccine Market, Size, Forecast 2023-2027Renub Research
Renub Research has recently released a report named "China Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2027," providing a detailed industry analysis that includes market share insights. In addition, the report covers research on competitors and regions and current advancements in the China Vaccine Market.
Ningbo Menovo Pharmaceutical Co., Ltd (Shanghai: 603538) is an international pharmaceutical enterprise which is professional in researching, producing and marketing API, biopharmaceuticals and finished drug products.
Presentation by Delia Grace, Bernard Bett, Theo Knight-Jones, Florence Mutua, Hung Nguyen, Himadri Pal and Kristina Roesel at the World One Health Congress, Singapore, 7–11 November 2022.
1- MarketingBefore putting the product into the market, the prod.docxmonicafrancis71118
1- Marketing
Before putting the product into the market, the product goes through several stages. One of the most important stages is to determine the price of the product. After that, it will be studied by asking questions to customers and anticipate their requirements in terms of shape, colour phrases recorded on it. It can be applied using servery or interview the customer. Finally, the product needs to be promoting before it is been released, so electronic, and visual and audio can be used as advertising. However, in this experiment, we will focus only on the total cost of the product and then work on finding who develops the product….[9] [10].
1.1 Estimating of the total price.
For the antibiotic spray, it can be estimate the total price depend on the type of the material which were be used. Thus, the material in the table estimates the total price.
Material
Discerption
Brand/ manufacture
Price Ink VAT.
[1] Cefuroxime(as Cefuroxime sodium) 1.5 gram.
CEFUROXIME is a cephalosporin antibiotic. It is used to treat certain kinds of bacterial infections. It will not work for colds, flu, or other viral infections
£4.70
[2] Sterile Water (1000ml)
Single Bottle of Sterile Water (1000ml)
Baxter
£3.54
[3] 73.5 mg of sodium
Sodium Bicarbonate 2kg - Pharmaceutical Grade (Bicarb/Bicarbonate of Soda)
£6.49
[1] Metronidazole
Metronidazole 500mg/100ml infusion 100ml bags (A A H Pharmaceuticals Ltd)
£63.86
[4] Phosphatebuffer (pKa=7.2)
PBS405.1 Virtual PHOSPHATE BUFFERED SALINE pH 7.4 10X Liquid Concentrate, 1L
£22.75
[5] Brilliant Blue FCF
1 kilogram
£6-8
[6] 100ml Stainless Steel
Empty stainless bottle spray
£7-9
Total price
£118
2- Companies and industry
There are many companies interested to work on or collaborate for developing the antibiotic. Following, there are some of the companies, Charities and universities, which they work hardly to improve public health and more specifically in the development of antibiotics. Thus, the product will be a focuses for them and new idea that can be started to develop and prove its effectiveness. Then, it can be put in the market, which many people can take advantage of the ease and licences of the product.
2.1. GSK Company [13]
At GSK, they are at the forefront of researching new ways to tackle some of the world’s biggest healthcare challenges. So as antibiotic resistance grows, they are investing in new ways to fight infection.
Their approach is to make the most of their own expertise and experience, while at the same time forming complementary partnerships and alliances with others who bring different kinds of expertise. Their vision for the world, where everyone has access to the vaccines they need, depends on a steady supply of great ideas and brilliant science. They have much to offer and through collaboration, they can achieve so much more.
For example, more than 90% of the vaccines in their pipeline are being developed in partnership with others. They have a long track rec.
Presentation by Clare Woods, Business Development Manager for MedTech, NIHR at Excel in Health: developing your innovation for business on Tuesday 12 March 2019 at the Innovation Centre, Daresbury.
One Health approach to address zoonotic and emerging infectious diseases and ...ILRI
Presentation by Hung Nguyen-Viet, Hu Suk Lee, Fred Unger, Arshnee Moodley, Eric Fèvre, Barbara Wieland, Bernard Bett, Michel Dione, Edward Okoth, Johanna Lindahl, Sinh Dang-Xuan and Delia Grace at the virtual 2020 Global ODA Forum for Sustainable Agricultural Development 9–10 November 2020.
I have created a brief presentation on how to fix problems of pandemics, such as Covid-19. Obviously, several more things, such as healthcare policy, immigration, and vaccination could have been covered but here are issues which few are focusing on and are immediate fixes.
09 CeoMeeting- Session 4- Medicines for MalariaMLSCF
Session 4: Health & Wellness
Title: The Changing Face Of Healthcare:
Where Are The Opportunities?
Special Speaker: Dr Chris Hentschel, Medicines for Malaria Venture
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
1. Environmental Prerequisites to Invest Pharmaceutical Sector in Developing Countries
在发展中国家投资药品产业所需要的环境
Helen Yang 杨光
Director, International Business Development
国际业务发展总监
Sinovac Biotech Co. Ltd.
北京科兴生物制品有限公司
June 12, 2012
2. Environment Expected to Invest in Pharmaceutical Sector in
(less) Developing Countries
1 Sinovac Profile
Sinovac’s Plan to Work with Africa
2
3
Company Overview
Going International
Influenza Vaccine Practices in South Africa and Kenya
What do the manufacturers concern?
-Key Requirements for Pharmaceutical Sector
-Drivers and Determinants
4. 4
• Provide Chinese children with the best vaccines in the
world,
• Let children in the developing world being benefited from
vaccines at affordable price;
Our mission is to supply vaccines to
eliminate human diseases.
Sinovac Biotech Ltd. (NASDAQ GSM: SVA)
5. 5
Supply Vaccine to Eliminate
Human Diseases
R&D
Manufacturing
Sales &
Marketing
Post-Sales
Services
H5N1
H1N1
6. 6
Five Key Strategic Objectives
.....
.....
.....
New Version of
Chinese Pharmacopeia
• October 2010
• February 2011
• February 2011
New Version of China
GMP Standards
NRA of China pass WHO
Pre qualification
Develop new products
to serve unmet medical
needs
Expand production capacity
to meet growing demand from
China and other developing
markets
Maintain high quality to
comply with
international standards
Maximize domestic sales
and achieve registration in
overseas markets
Seek international
collaborations to leverage
competitive advantages
and share benefits with
partners
Develop more vaccines against more types of disease
Provide high quality products at affordable prices
Deliver products in China and around the globe
7. Path to “Go International”
Local Registration
& Distribution
Through Local
Partner
Local Partnership
for Joint
Investment
Local Investment
Why: Sufficient Capacity, Efficient Supply, Affordable Price for Developing
Countries?
8. Current Distributors & Target Markets
Mexico
Venezuela
Peru
Chile
Algeria
Egypt
Saudi
Uzbekistan
Mongolia
Nepal
India
Pakistan
ThailandVietnam
Philippines
Malaysia
Korea
Ukraine
Turkey
Israel
Registration Process x6Local Distribution x3 Target Markets in 2012 x15
Kenya
Brazil
Columbia
Argentina
9. Human Vaccines Animal Vaccine
Current Product Portfolio
1st inactivated Hepatitis A vaccine developed, produced,
and marketed by a Chinese manufacturer
Better safety profile than the counterpart
Primarily sold in China; start to sell into overseas market
About 30million doses sold in China since the beginning;
1st inactivated hepatitis A and B vaccine produced in China
The only supplier in China
1st locally produced flu vaccine without preservative;
First IVS (Influenza Vaccine Supply) task force member from
developing country
Primarily sold in China; start to sell into overseas market
First and only approved H5N1 vaccine in China
Only qualified H5N1 vaccine (against avian flu) for Chinese
government stockpiling program
1st company globally to receive production license for H1N1
vaccine
Inactivated animal rabies vaccine
Locally occurring virus strain, which improves the
protective effect
Replicate quality control system for human
vaccines to guarantee the quality of animal
vaccines
Competitively priced compared with similar
products imported
~80 million registered dogs in China
Healive
Bilive
Anflu
Panflu
Panflu.1
RabEnd
10. Deep Pipeline to Drive Future Growth
Human Vaccines
• EV71 Vaccine (hand, foot
and mouth disease)
• Pneumococcal Conjugate Vaccine
(PCV)
Clinical Trials
Over 1.6 million cases reported in China with 506
fatalities in 2011.
~80M children (children aged 5 and under in China)
Target Population:
~32M children (children aged 2 and under in China)
Over 350 million people over age 50
• Mumps Vaccine
• Rubella Vaccine
• Long-term objective to launch MMR vaccine within 5
years
• In 2011, 26.3 million doses of MMR were approved
and released in China.
• Rotavirus Vaccine
• Pneumococcal Polysaccharides
Vaccine (PPV)
• Chickenpox Vaccine (Varicella) • 14.2 million doses supplied in China in 2011
•Potentially being included in public market
• Rabies Vaccine for Humans • In 2011, 11.55 million doses of rabies vaccines
were approved and released in China
P1 P2 P3
Pipeline Market Potential
Pre-
Clinical
File
IND
Clinical Trials Reg.
• 5.8 million doses of vaccines for rotavirus were
approved for sale in China in 2011
11. Manufacturing Facilities
State-of-the-Art-Facilities
Headquarter- Beijing Beijing
Dalian
Tangshan
Filling & Packaging Plant
Flu Plant
R & D Center
Dalian Site
Tangshan Site-Animal Vaccine
Changping site, Beijing
PUK Bio-city
In China, Sinovac possesses commercial production sites of total 160,000 m2
12. Environment Expected to Invest in Pharmaceutical Sector in
(less) Developing Countries
2
What do the manufacturers concern?
-Key Requirements for Pharmaceutical Sector
-Drivers and Determinants
13. What do the manufacturers concern? General preconditions for most
industrial investment
Political Environment Economic Environment
Social, Cultural and Natural Environment Technical Environment
Legal & Regulatory Environment
Political System
-Administration
-Legislation
-Justice
…
Major Parties
-…
-…
-…
Industrial Survey
GDP, GNI, CPI…
Development
Stage
Import & Export
…
Natural Environment
-Geography & Climate
-Energy
-Communication & Transportation
…
Social & Cultural Environment
-Races, language
-Demographics
Education
Colleges &
Institutes
Encouraging
Industries
International
cooperation
…
Special Local Laws
Revenue System
…
Major Laws for Investment
I.P. Laws
Foreign Currency Management
…
Political Stability Investment landscape in Sub-Saharan Africa
14. What do the manufacturers concern?
Key Requirements for Pharmaceutical Sector
Skilled human resources: pharmacists; graduates in pharmacy, chemistry, biochemistry...; technicians; marketing&sales.
Quality of scientific education…
Local Business management schools and graduates returning of foreign business schools…
Reliable power and clean water;
Special industrial zones…
Capable to encourage foreign investment into the local pharmaceutical industry;
Builds confidence to export to other countries.
Human Resources
Basic Infrastructure
Functioning National Drug Regulatory Authority
15. What do the manufacturers concern? (Con’t)
Drivers and Determinants
Market Size.
Long term plan in the country or in the area.
Flagship or pipeline products, or distribution network driven M&A, JV.
Take advantage of efficiencies and lower costs by consolidation.
Eg. Moving R&D activities to China and India.
Work in R&D with institutes or universities of developing countries.
Registration requirements, pricing.
Intellectual property.
Foreign investment incentive policy.
Market Access
Seeking Efficiency
Policies Facilitation & Incentive
Aside from economic motives, humanitarian concerns only.
Eg. HIV and AIDS local R&D or production.
Humanitarian and Moral Drive
16. Conclusion - Near-Term Solution
Understand
the Culture
Understand
the
regulations
Access to
the
resources
Gain market
access
……
17. Sinovac’s Plan to Work with Africa3
Influenza Vaccine Practices in South Africa and Kenya
18. Sinovac’s Plan to work with Africa - Case sharing
Countries
Flu vaccine
Consumption 2009
(thousand doses)
Immunization
Rate
South Africa 1,103 2.20%
Mauritius 52 4.00%
Kenya 20 0.05%
Cameroon 10 0.05%
Angola 10 0.05%
Namibia 9 0.40%
Burkina Faso 8 0.05%
Mali 8 0.05%
Zambia 7 0.05%
Botswana 6 0.28%
Benin 4 0.05%
Total 1,237
Step 1. Political Stability--South Africa & Kenya
Conclusion:
Possible to launch business.
Step 2. Environment Evaluation Checklist
Political; Economic; Social&& Cultural& Natural;
Technical; Laws& Regulatory.
Step 3. Flu Vaccine Market Research
Local production; Size; Pricing; Competitions;
Distribution…
Step 4. Launching Plan
FDI? M&A? JV? Distributor?
Suspending for WHO PQ?
Step1 Step2 Step3
Local Production:
A PPP company
is under
establishment to
manufacture flu
vaccine and
others.
Regulatory Gap:
1. EU format
dossier;
2. Local pre-
licencing
clinical trial.
OK
Step4
Suspending
South Africa
Step1 Step2 Step3
Market size is
relative small, but
foresee the future
development
and covering
other African
countries.
OKOK
Step4
Distributor
Kenya
Local
Production
*Provision of seasonal influenza vaccines in 157 countries (2004 – 2009), IFPMA.
